Nandita

Mani

MD

Bio

Dr. Mani is an infectious diseases specialist at UW Medicine. She is a Clinical Instructor in the Division of Allergy and Infectious Diseases, the Medical Director of Employee Health at UW Medical Center, and the Associate Medical Director of Infection Prevention at UW Medical Center. In the hospital and in her clinic, she cares for patients with complex infectious diseases. She strives to provide compassionate, high-quality care to all patients and their families and believes that understanding individual preferences and values is essential to patient care. 

Research Interests

• Healthcare-associated infections
• Antimicrobial stewardship

Clinical Interests

• General Infectious Diseases
• Travel Medicine
   

Education & Training

BA, University of Virginia (2009)

MD, Georgetown University School of Medicine (2014)

Residency, Internal Medicine, University of Washington (2017)

Fellowship, Infectious Diseases, University of Washington (2020)
 

Honors

Alpha Omega Alpha Medical Honor Society (2013)

Resident Poster Presentation Award, American College of Physicians Washington Spring Scientific Scholarship Meeting (2016)

Safety Heroes Award, UWMC (2022)

Publications

1.     Mani NS, Lynch JB, Fang FC, Chan JD. Risk Factors for BI/NAP1/027 Clostridioides difficile Infections and Clinical Outcomes Compared to Non-NAP1 Strains. Open Forum Infect Dis. 2019 Oct 12; 6(12): ofz433.  

2.     Mani NS, Budak JZ, Lan KF, et al. Prevalence of COVID-19 Infection and Outcomes Among Symptomatic Healthcare Workers in Seattle, Washington. Clin Infect Dis.  2020 June 16; ciaa761. doi:10.1093/cid/ciaa761  

3.    Mani NS, Lan KF, Jain R, et al. Post-Prescription Review with Threat of Infectious Diseases Consultation and Sustained Reduction in Meropenem Use over Four Years. Clin Infect Dis. 2020 Aug 31; https://doi.org/10.1093/cid/ciaa1279  

4.     Bradley BT, Bryan A, Fink SL, Goecker EA, Roychoudhury P, Huang ML, Zhu H, Chaudhary A, Madarampalli B, Lu JYC, Strand K, Whimbey E, Bryson-Cahn C, Schippers A, Mani NS, Pepper G, Jerome KR, Morishima C, Coombs RW, Wener M, Cohen S, Greninger AL. Anti-SARS-CoV-2 Antibody Levels Measured by the AdviseDx SARS-CoV-2 Assay Are Concordant with Previously Available Serologic Assays but Are Not Fully Predictive of Sterilizing Immunity. J Clin Microbiol. 2021 Aug 18;59(9):e0098921. doi: 10.1128/JCM.00989-21. Epub 2021 Aug 18. PMID: 34165323; PMCID: PMC8373027. 

5.     Risa E, Roach D, Budak JZ, Hebert C, Chan JD, Mani NS, Bryson-Cahn C, Town J, Johnson NJ. Characterization of Secondary Bacterial Infections and Antibiotic Use in Mechanically Ventilated Patients With COVID-19 Induced Acute Respiratory Distress Syndrome. J Intensive Care Med. 2021 Oct;36(10):1167-1175. doi: 10.1177/08850666211021745. Epub 2021 Aug 10. PMID: 34372721; PMCID: PMC8358424. 

6.    McEwen AE, Cohen S, Bryson-Cahn C, Liu C, Pergam SA, Lynch J, Schippers A, Strand K, Whimbey E, Mani NS, Zelikoff AJ, Makarewicz VA, Brown ER, Bakhash SAM, Baker NR, Castor J, Livingston RJ, Huang ML, Jerome KR, Greninger AL, Roychoudhury P. Variants of Concern Are Overrepresented Among Postvaccination Breakthrough Infections of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Washington State. Clin Infect Dis. 2022 Mar 23;74(6):1089-1092. doi: 10.1093/cid/ciab581. PMID: 34166484; PMCID: PMC8394820. 

7.    Chung SH, Wener M, Bays AM, Rahbar H, Morishima C, Bryan AB, Fink SL, Cohen S, Mani NS, Chaudhary A, Gardner GC. Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli et al. Ann Rheum Dis. 2021 Oct;80(10):e165. doi: 10.1136/annrheumdis-2021-220957. Epub 2021 Aug 2. PMID: 34340981.